Elekta prides itself on consistently striving to do the right thing – our employees, customers and, most importantly, people living with cancer are counting on us.

This will advance patient care and outcomes. We are proud to be the first center in Australia to offer Elekta Unity to our patients and are excited to be at the forefront of MR/RT research and education.

The real-time images that Elekta Unity provides enables unprecedented precision in delivering therapeutic radiation, particularly to anatomies that can be clearly seen on MR images, and those which change or move during the treatment course.

The Elekta Unity MR-Linac abstracts presented at ASTRO add to the existing body of literature, which now comprises more than 210 peer-reviewed publications demonstrating the current value and future potential of high-field MR-guided radiation therapy.

We are delighted to be part of Elekta’s group of trusted third-party partners.

Elekta Unity will enable us to deliver higher doses of radiation while sparing healthy tissue and help patients to complete their treatment more quickly. It will also allow us to use radiation therapy for hard to treat cancers for which traditional radiation therapy approaches may not be feasible.

We reserve our Medical Device Engineering Breakthrough award for recognizing transformative technology and Elekta Unity is a shining example of groundbreaking medical technology deserving of this designation.

As the most advanced approach to radiation therapy, Unity gives us the ability to adapt treatment in real time to optimize radiation delivery to the tumor while sparing nearby healthy tissue.

Elekta is proud that the National Cancer Hospital has chosen our equipment and solutions and that we can play a role in making this essential therapy available to more people and offer the potential to save thousands of lives.

Elekta relentlessly pursues the advancement of treatment quality assurance – through innovation, collaboration or procurement – by elevating quality control at all stages of the workflow.

We are honored to have received this prestigious design award, which further illustrates our commitment to designing patient-centric technologies that allow clinicians to deliver the best quality cancer care worldwide.

We are pleased to have achieved this important milestone toward making Elekta Unity available in Canada and expect that this important new treatment option will become available to patients later this year.

Throughout the last 13 years of our center’s service to patients, our mission has been to provide the highest level of healthcare. The Versa HD system’s advanced cancer treatment capabilities are in perfect harmony with that mission.

The ability to scan, plan and treat in real time has been the long-sought vision of radiation oncologists. These features of Elekta Unity make it especially promising in treating tumors that shift in size and shape in the body.

Each treatment session on this innovative system is an opportunity to gain insight into the benefits that this technology provides and, critically, to determine which patients benefit from MR/RT therapy.

Category Leaders are committed to providing the very best technology, service, and guidance to providers and payers.

We believe that clinicians and patients in the UAE and around the world should have access to life-saving, world-class cancer care.

We are honored that the patient- and user-centered design that we contributed to Elekta Unity has been recognized as a critical component of this innovative and precision technology.

Radiation therapy is a highly effective, yet underutilized, form of cancer treatment, so we are pleased to be increasing access to this targeted technology through this new order for Elekta Versa HD linear accelerators.

The MR-linac studies presented at ASTRO add to the solid foundation of data demonstrating how MRgRT (magnetic resonance guided radiation therapy) can address some of the historic challenges to balancing effective delivery of radiation to tumors while protecting nearby tissues and organs at risk. This has the potential to improve outcomes for cancer patients.

Since 2014, Elekta has been an important factor in our ability to provide the patients we serve with cutting-edge technologies and we are pleased to expand our relationship by advancing the clinical utility of Elekta Unity.

Our focus on precision radiation medicine reflects our commitment to innovating solutions that enable personalized radiation therapy that can rapidly be adapted to changes in tumor size and shape and use intelligent data processing to streamline treatments.

Together we’ve made world-leading advances in radiotherapy through our research and we expect Elekta Unity to allow us to make another step change in improving cancer treatment.

We are very happy that the NHS is investing in this essential treatment modality – brachytherapy can offer unsurpassed accuracy and efficiency in treatment delivery.

Elekta Unity is now a reality, and we are excited to start treating our patients. The ability to see what we treat in real time and adapt treatment on a daily basis enables unprecedented precision and ensures that each patient receives the right dose, delivered to the right location, at every treatment session.

Our team in Crawley will be able to interact with healthcare providers visiting from anywhere in the world, as they jointly collaborate and share ideas on technological solutions to address the global cancer burden.

This is a paradigm shift for radiotherapy. The new MR-linac will allow us to see soft tissue during treatment with unprecedented accuracy.

Elekta Unity represents a new paradigm of precision radiotherapy that enables a scan-plan-treat approach, and supports personalized regimens that meet the unique needs of the individual patients’ anatomy.

The combination of Elekta’s experience and York Instruments’ advanced technology provides an exciting new future for MEG.

On behalf of the Government of Jordan, I wish to express our sincere thanks and gratitude to Elekta for this responsible act of generosity and humanity.

The new Elekta equipment will help us achieve optimal outcomes for our cancer patients by consistently applying best practices in patient care and treatment.

Elekta is not only the leading innovator of today’s radiation oncology solutions, it is also the partner of choice for providing a complete package of patient-centric radiation therapy care options in an evolving technology and healthcare economic landscape.

Our collaboration with IBA and Equicare is just one example of how we are building a strong network of key ‘best of breed’ vendors as part of our partnerships and open connectivity.

Richard Hausmann, CEO

Worldwide demand for stereotactic treatments are increasing, especially among the 20 to 40 percent of cancer patients who will develop brain metastases.

Breakthroughs in clinical and scientific cancer research are increasing what we know about cancer. Consequently, Elekta is delivering new precision treatment modalities and digital solutions so that clinicians can better plan, treat and monitor outcomes for each individual patient – and population.

Elekta has been at the forefront of the digital healthcare revolution, and we are committed to working with other leaders in the field to establish value-added solutions that offer complete connectivity and interoperability with MOSAIQ and our other digital solutions.

Peter Gaccione, Executive Vice President, Region North & Latin America

We are very pleased that the Egyptian government continues to rely on Elekta solutions to provide the best treatment for the country’s cancer patients.

The enthusiasm of these world-class cancer institutions to the clinical implementation of the MR-linac reflects the belief that this breakthrough technology will address real unmet needs.

Our MR-linac system is truly groundbreaking because it overcomes the technical barriers that have hindered the integration of radiation therapy with real-time high-field imaging.

“Elekta’s MR-linac is designed to enable precise tumor targeting through visualizing the target and surrounding organs at risk in real time.”